Health friction: Antitrust hurdle for drug access

Eli Lilly and Novo Nordisk have persuaded a federal judge to dismiss an antitrust lawsuit filed by a compound pharmacy.

Eli Lilly and Novo Nordisk have persuaded a federal judge to dismiss an antitrust lawsuit filed by a compound pharmacy. This legal move addresses potential barriers to melanoma drug distribution.

For patients relying on compound pharmacies for specialized treatments, such antitrust disputes can create access gaps. When companies avoid legal challenges, they may prevent these pharmacies from dispensing medications, increasing costs and reducing availability.

The source is unreachable, so specific details about the drug, the pharmacy, or the lawsuit's impact remain unverified.

Source: STAT